en · de · es
sr9009-notes.peptides1004.com › Topic › Sr9009 Background And Receptor Mechanism — Research Overview

Sr9009 Background And Receptor Mechanism — Research Overview

By Editorial Desk · published 2025-12-06 · last reviewed 2026-01-27 · Topic

LC-MS comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.

Last reviewed on 2026-01-27. Where a claim depends on a specific study, the study is described rather than over-claimed.

SR9009 Background and Receptor Mechanism

SR9009 is a synthetic small molecule studied as an agonist of REV-ERB nuclear receptors. REV-ERB alpha and REV-ERB beta help regulate circadian rhythms and metabolic gene expression. In laboratory research, SR9009 has been used to probe how these receptors affect skeletal muscle, liver, and adipose tissue. The compound was identified in academic drug-discovery work and is often described in scientific literature by its chemical name and research code. It is not an approved medicine, and human clinical data remain limited or absent.

SR9009 binds REV-ERB receptors and alters their repressive activity on target genes. This action can change transcription of genes involved in lipid handling, glucose metabolism, and mitochondrial function. In rodent studies, treated animals have shown changes in muscle oxidative capacity and exercise performance, though effects vary by dose, duration, and model. The precise molecular steps connecting receptor binding to whole-body outcomes are still an active area of investigation. Findings in animals do not automatically translate to humans.

Analytical Detection and Stability

Stability depends on physical form, temperature, light exposure, and solvent. Solid SR9009 is generally stored cold and dry, with protection from light to limit degradation. Dimethyl sulfoxide stocks are common for laboratory work, but repeated freeze-thaw cycles can reduce compound integrity. Aqueous solutions may be less stable than organic stocks, and the ethyl ester in the structure can be susceptible to hydrolysis under certain conditions. Researchers typically validate storage conditions and recheck purity before quantitative experiments, especially when using archived material.

Regulatory treatment of SR9009 varies by country and region. It is not approved as a pharmaceutical, and several jurisdictions restrict its sale for human consumption. Some authorities classify it as a research chemical, a prescription-only substance, or a prohibited performance-enhancing agent in sport. Purchasers may encounter certificates of analysis, but these documents do not guarantee identity, purity, or legality. In research settings, institutional safety reviews and controlled procurement help ensure that materials are handled under appropriate oversight. The absence of harmonized rules means that legal status can change and requires verification.

Analytical identification of SR9009 typically relies on liquid chromatography coupled with tandem mass spectrometry. In biological samples, researchers first separate the compound from matrix components using protein precipitation, liquid-liquid extraction, or solid-phase extraction. High-performance liquid chromatography with ultraviolet detection and nuclear magnetic resonance spectroscopy can support structural confirmation of reference materials. Because SR9009 is a small, relatively lipophilic molecule, reverse-phase columns and acidic mobile phases are common. Laboratories often include isotope-labeled internal standards to improve quantification and to correct for ion suppression.

Sr9009 at a glance

PropertyValueNotes
Chemical classSynthetic REV-ERB agonistSmall-molecule nuclear receptor ligand
AppearanceOff-white to pale yellow solidTypical for research-grade powder
Solubility classSoluble in DMSO; low water solubilityCommon stock solutions use organic solvent
Typical stock solventDimethyl sulfoxideUsed for laboratory assays
Common analytical methodHPLC with UV or mass detectionUsed for identity and purity checks

Background and Receptor Pharmacology

Regulatory and sporting contexts treat SR9009 as a prohibited substance in many elite competitions. Its presence on banned lists reflects concerns about performance enhancement and unknown long-term safety. Analytical chemists have developed methods to detect the parent compound and its metabolites in urine and blood. Literature discussions distinguish between in vitro potency, animal pharmacology, and anecdotal human reports. The latter are difficult to verify because products sold online may lack purity or contain different compounds.

SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. These receptors help regulate circadian rhythms, lipid metabolism, and inflammatory gene expression. In cell and animal experiments, SR9009 alters transcription of clock-controlled genes and metabolic pathways. The compound is not a hormone and does not resemble classical steroid structures. Its activity depends on binding to the ligand-binding domain of REV-ERB, where it can modify corepressor recruitment.

Research interest in SR9009 grew from studies of circadian biology and metabolic disease. Preclinical reports describe effects on exercise capacity, muscle metabolism, and blood lipid levels in rodents, but these findings come from controlled laboratory settings. The compound has low oral bioavailability in animals, which limits systemic exposure after swallowing. Investigators often use injected routes in experiments to achieve measurable plasma concentrations. Human clinical data are sparse, no approved therapeutic product exists, and whether animal effects translate to humans remains an open question.

Related pages on this site

Detection, Regulation, and Misconceptions

Several misconceptions surround SR9009. It is often described as a SARM, a steroid, or an exercise pill, but its known target is the REV-ERB receptor family. Rodent studies have examined exercise capacity and metabolic markers, yet human outcomes remain unproven. Oral bioavailability appears low in animals, and human pharmacokinetics are not well characterized. Online products may contain impurities or different compounds, so identity and purity testing are important for research use.

Analytical chemists detect SR9009 with liquid chromatography-tandem mass spectrometry, commonly abbreviated LC-MS/MS. Sample preparation may involve protein precipitation, liquid-liquid extraction, or solid-phase extraction before analysis. Laboratories can target the parent compound or its metabolites, depending on the matrix and the purpose of testing. Anti-doping methods require sensitive and specific assays because concentrations in biological samples can be low. Reference standards and validated methods are essential for reliable identification and quantification.

Background and Mechanism of SR9009

Mechanistically, SR9009 binds the ligand-binding domain of REV-ERBα/β and enhances recruitment of corepressor complexes. This represses target genes rather than activating them. Because REV-ERB proteins normally compete with ROR proteins at shared response elements, the net effect depends on tissue and timing. Researchers use SR9009 to probe how nuclear receptor signaling links the clock to metabolism, inflammation, and muscle biology. Findings are largely preclinical, and the precise contribution of each receptor subtype remains under study.

SR9009 is frequently discussed in fitness and research-chemical contexts, yet it has no approved medical indication. Regulatory agencies have not authorized it for human use, and it is not a standard prescription drug. Some sports organizations list it as a prohibited substance because of its potential performance-enhancing properties. Published human data are sparse, so claims about its effects in people often rely on animal models or anecdotal reports. Quality and identity of online materials can vary widely.

SR9009 is a synthetic small molecule studied as a REV-ERB agonist. REV-ERBα and REV-ERBβ are nuclear receptors that help regulate circadian rhythms and metabolic gene expression. The compound was identified in academic screening efforts to find synthetic ligands for these receptors. In cell and animal studies, SR9009 alters transcription of genes involved in lipid and glucose metabolism, and it can shift circadian behavior. It is not an approved therapeutic agent.

Identity, Handling, and Regulation

Regulatory status varies by country and intended use. Major drug agencies have not granted marketing authorization for SR9009 as a medicine, and it is not listed as a controlled substance in many jurisdictions. It is often sold as a research chemical, a category that may fall outside pharmaceutical manufacturing rules. Buyers should verify local laws and supplier documentation, including certificates of analysis. The lack of standardized quality controls raises concerns about identity, purity, and actual content in products marketed online.

In laboratory settings, SR9009 is commonly identified by its molecular structure and its interaction with REV-ERB receptors. Vendors may list it under synonyms such as Stenabolic or REV-ERB agonist, but those names do not define purity or identity. Analytical confirmation typically uses high-performance liquid chromatography with ultraviolet detection or liquid chromatography–mass spectrometry. A reference standard is needed to compare retention time and mass spectrum, because the compound can be confused with related research chemicals.

Reference notes

The manufacturer recommends a "double pour" serve, which according to Diageo should take two minutes. Guinness has promoted this wait with advertising campaigns such as "good things come to those who wait". The brewer recommends that draught Guinness should be served at 6–7 °C (42.8 °F), while Extra Cold Guinness should be served at 3.5 °C (38.6 °F). Before the 21st century, it was popular to serve Guinness at cellar temperature (about 13 °C) and most drinkers preferred it at room temperature (about 20 °C). According to Esquire magazine, a pint of Guinness should be served in a slightly tulip-shaped pint glass, rather than the taller European tulip or 'Nonic' glass, which contains a ridge approx 3/4 of the way up the glass. To begin the pour, the server holds the glass at a 45° angle below the tap and fills the glass 3/4 full. On the way out of the tap, the beer is forced at high speed through a five-hole disc restrictor plate at the end of the tap, creating friction and forcing the creation of small nitrogen bubbles which form a creamy head. The server brings the glass from 45° angle to a vertical position. After allowing the initial pour to settle, the server pushes the tap handle back and fills the remainder of the glass until the head forms a slight dome over the top of the glass (or "just proud of the rim"). Guinness recommends that, to avoid the bitter taste of the nitrogen foam head, gulps should be taken from the glass rather than sipping the drink. In 2010, Guinness redesigned their pint glass for the first time in a decade.

February 3 – The government shutdown ends with a bill that funds DHS for two weeks. February 4 The Central Intelligence Agency announces it will no longer publish The World Factbook. Decline of newspapers: The Washington Post announces 300 journalist layoffs, roughly one-third of its employees, as part of a major restructuring. February 5 The New START treaty limiting strategic nuclear weapons with Russia expires. Three people are killed and seven others are injured when a car crashes into a 99 Ranch Market in Westwood, Los Angeles, California. February 6 – Trump shares a video on social media depicting Barack and Michelle Obama as apes. Trump receives bipartisan condemnation. February 8 – Super Bowl LX is played at Levi's Stadium in Santa Clara, California, with the Seattle Seahawks prevailing over the New England Patriots. Bad Bunny headlines the halftime show with special guests Lady Gaga and Ricky Martin, while Kid Rock performs at the Turning Point alternate All-American Halftime Show. February 10 – Trump threatens the opening of the Gordie Howe International Bridge, saying the U.S. should be "fully compensated for everything" it has given to Canada, and demanding that Ottawa "treats the United States with the Fairness and Respect that we deserve". February 11 – The Federal Aviation Administration abruptly announces a 10-day temporary flight restriction (TFR) over El Paso, Texas and surrounding areas (specifically a 10-mile radius surrounding El Paso International Airport).

Neutrino experiments include ICARUS and MicroBooNE, both of which use high-purity liquid argon in a time projection chamber for fine grained three-dimensional imaging of neutrino interactions. At Linköping University, Sweden, the inert gas is being utilized in a vacuum chamber in which plasma is introduced to ionize metallic films. This process results in a film usable for manufacturing computer processors. The new process would eliminate the need for chemical baths and use of expensive, dangerous and rare materials.

Low-density lipoprotein receptor-related protein 5 is a protein that in humans is encoded by the LRP5 gene. LRP5 is a key component of the LRP5/LRP6/Frizzled co-receptor group that is involved in canonical Wnt pathway. Mutations in LRP5 can lead to considerable changes in bone mass. A loss-of-function mutation causes osteoporosis pseudoglioma syndrome with a decrease in bone mass, while a gain-of-function mutation causes drastic increases in bone mass.

Sources: en.wikipedia.org

Reference notes

Nitrate reductase (NADPH) (EC 1.7.1.3, assimilatory nitrate reductase, assimilatory reduced nicotinamide adenine dinucleotide phosphate-nitrate reductase, NADPH-nitrate reductase, assimilatory NADPH-nitrate reductase, triphosphopyridine nucleotide-nitrate reductase, NADPH:nitrate reductase, nitrate reductase (NADPH2), NADPH2:nitrate oxidoreductase) is an enzyme with systematic name nitrite:NADP+ oxidoreductase. This enzyme catalises the following chemical reaction

==== Lieutenant of the Royal Victorian Order (LVO) ==== Hamish Blair, Senior Executive Officer, Scottish Office. Captain Robert Neil Blair, Royal Navy, Private Secretary to The Duke of York and to Princess Alexandra, the Honourable Lady Ogilvy. Laurence Albert Brown. For services to the Royal Collection. Donald Reeve Buttress, Surveyor of the Fabric, Westminster Abbey. Bernard Joseph Frahm, . For services to the Crown on Royal Visits to New Zealand. Commander Thomas Dixon Laidlaw, , Metropolitan Police. Leonora Mary, The Countess of Lichfield, Extra Lady in Waiting to The Princess Royal. Allan Arthur Percival, lately Press Secretary to The Prince of Wales. Alexander Hay Sutherland, Chief Publicity Officer, Scottish Office.

== References == Connaughton, R.M. (1992) [1988]. The War of the Rising Sun and Tumbling Bear: A Military History of the Russo-Japanese War 1904-5 (Reprint ed.). Routledge. ISBN 978-0415071437. Kajima, Morinosuke (1976). The Diplomacy of Japan, 1894-1922. Vol. 1: Sino-Japanese War and Triple Intervention. Tokyo: Kajima Institute of International Peace. Kowner, Rotem (2006). Historical Dictionary of the Russo-Japanese War. Scarecrow Press. ISBN 0-8108-4927-5.

Outside of the main cities, signposted walks follow rivers and the escarpment of the Pennines, which is scaled in meandering stages and tunnels by the recreational Leeds-Liverpool Canal and Rochdale Canal, navigable by barge, canoe or kayak. The Yorkshire Sculpture Park and The Hepworth in Wakefield are major national art attractions, while Haworth is visited for being the home of the Bronte Sisters. Ilkley, Otley, Hebden Bridge and Holmfirth are popular smaller towns featuring farmer's markets, breweries, tea rooms, stately homes and are popular with hikers.

== Biosynthesis == The amino acid tyrosine is metabolised in a series of reactions, one of which is catalysed by homogentisate 1,2-dioxygenase. This converts the intermediate homogentisic acid into 4-maleylacetoacetic acid.

Sources: en.wikipedia.org

Frequently asked questions

What is SR9009?

SR9009 is a synthetic research compound that acts on REV-ERB nuclear receptors. It is not approved for human use and is sold only as a research chemical. Its effects have been studied mainly in cells and rodents.

How does SR9009 work?

It binds REV-ERB alpha and REV-ERB beta and changes the expression of genes tied to metabolism and circadian rhythm. These changes can affect mitochondria and energy use in animal models. The exact chain from receptor binding to physiological outcome is still being mapped.

Is SR9009 a proven performance enhancer?

No reliable human trials show that SR9009 improves athletic performance. Some rodent studies report endurance changes, but these results are not proof of human benefit. Its use in sport is prohibited, and quality and safety data are lacking.

How is SR9009 measured in samples?

The most common approach is liquid chromatography-tandem mass spectrometry, often after extraction from blood, urine, or tissue. Ultraviolet detection and nuclear magnetic resonance spectroscopy are used mainly for reference material characterization. Isotope-labeled internal standards improve accuracy.

Network